Gross Profit, Operating Income, and Net Income as a percentage of Revenue

Operating Margin

Profit Margin

Margins

An operating expense is an expense a business incurs through its normal business operations. Often abbreviated as OPEX.

Collaboration expense, net

Operating Expenses

Year over year growth in Revenue and Operating Expenses.

Revenue Y/Y

OpEx Y/Y

Growth

Shares outstanding refer to a company's stock currently held by all its shareholders, including share blocks held by institutional investors and restricted shares owned by the company's officers and insiders.

Outstanding Shares

Market Cap

Also known as Price/Sales Ratio. Calculated using Average market cap for the quarter / Annualized quarterly revenue.

Revenue Multiple

CRISPR Therapeutics

CRISPR Therapeutics AG is a gene editing company, which engages in the development of transformative gene-based medicines for serious diseases using its proprietary CRISPR/Cas9 platform. Its CRISPR/Cas9 platform is a gene editing technology that allows for precise, directed changes to genomic DNA. The firm offers a portfolio of therapeutic programs across a broad range of disease areas including hemoglobinopathies, oncology, regenerative medicine, and rare diseases. The company was founded by Rodger Novak, Emmanuelle Charpentier, Shaun Patrick Foy, Matthew Porteus, Daniel Anderson, Chad Cowan and Craig Mellow on October 31, 2013 and is headquartered in Zug, Switzerland.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

CRISPR Therapeutics AG is a gene editing company, which engages in the development of transformative gene-based medicines for serious diseases using its proprietary CRISPR/Cas9 platform. Its CRISPR/Cas9 platform is a gene editing technology that allows for precise, directed changes to genomic DNA. The firm offers a portfolio of therapeutic programs across a broad range of disease areas including hemoglobinopathies, oncology, regenerative medicine, and rare diseases. The company was founded by Rodger Novak, Emmanuelle Charpentier, Shaun Patrick Foy, Matthew Porteus, Daniel Anderson, Chad Cowan, and Craig Mellow on October 31, 2013 and is headquartered in Zug, Switzerland.

ACADIA Pharma

Exelixis

Biotech is still one of the most exciting sectors on the market. Recession-proof, the sector is still thriving with millions of retiring baby boomers, mergers and acquisitions, new innovation, the introduction of artificial intelligence with drug discovery and demand for new treatments.

3 Biotech Stocks With the Strongest Clinical Pipelines

CRISPR Therapeutics could soon have an approved product in its portfolio. The stock's modest valuation suggests there could be significant upside.

Why CRISPR Therapeutics Stock Could Be About to Take Off

There's nothing like a convincing quarterly earnings beat. The gene-editing specialist's net loss was far narrower than expected.

Why CRISPR Therapeutics Stock Crushed the Market Today

CRISPR Therapeutics (CRSP) beats the mark for earnings and misses the same for sales in the third quarter.

CRISPR Therapeutics (CRSP) Q3 Loss Narrower Than Expected

From a technical perspective, CRISPR Therapeutics AG (CRSP) is looking like an interesting pick, as it just reached a key level of support. CRSP recently overtook the 200-day moving average, and this suggests a long-term bullish trend.

CRISPR Therapeutics AG (CRSP) Recently Broke Out Above the 200-Day Moving Average

-Advisory Committee meeting for exagamglogene autotemcel (exa-cel) for the treatment of severe sickle cell disease (SCD) completed October 31, 2023; exa-cel assigned Prescription Drug User Fee Act (PDUFA) target action date of December 8, 2023 for SCD-

CRISPR Therapeutics Provides Business Update and Reports Third Quarter 2023 Financial Results

-CTX310™ led to durable reductions of angiopoietin-like 3 protein (ANGPTL3) and triglyceride levels in non-human primates (NHPs) after a single dose-

CRISPR Therapeutics Announces Preclinical Data at the American Heart Association (AHA) Scientific Sessions 2023

Beam Therapeutics

Biotech stocks have been under extreme pressure over the prior 24 months. This industry-wide move lower may have created a handful of once-in-a-lifetime opportunities for investors.

2 Magnificent Growth Stocks That Might Be Badly Mispriced Right Now

Gene therapy has been on a roller-coaster ride since the first patient was treated 33 years ago. This slow-motion story took another turn this week after a panel of experts potentially set the stage for the first CRISPR/Cas9-based therapy to hit the market next year.

Why CRISPR Therapeutics Stock Charged Northward This Week

Vertex Pharmaceuticals

Vertex Pharmaceuticals and CRISPR Therapeutics just met with regulators at the Food and Drug Administration. The discussion was about the safety of their gene therapy candidate called exa-cel.

Here's What Investors Need to Know About Vertex Pharmaceuticals and CRISPR Therapeutics' Big Day at the FDA

Johnson & Johnson

Medtronic

One of these players is approaching a big milestone: potential product approval. The other two companies recently made moves to transform their businesses, and this may spur a new chapter of growth.

3 Healthcare Stocks to Buy Hand Over Fist in November

CRISPR Therapeutics AG (CRSP) is looking like an interesting pick from a technical perspective, as the company reached a key level of support. Recently, CRSP crossed above the 20-day moving average, suggesting a short-term bullish trend.

CRISPR Therapeutics AG (CRSP) Crossed Above the 20-Day Moving Average: What That Means for Investors

The mean of analysts' price targets for CRISPR Therapeutics AG (CRSP) points to a 108.5% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.

Wall Street Analysts See a 108.46% Upside in CRISPR Therapeutics AG (CRSP): Can the Stock Really Move This High?

CRISPR Therapeutics' first gene-editing candidate is moving closer to the finish line. An FDA advisory meeting this week set a positive tone ahead of a big regulatory decision.

One Month Ahead of its Most Crucial Moment Ever, Should You Buy CRISPR Therapeutics?

CRISPR Therapeutics AG (CRSP) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further price increase in the near term.

CRISPR Therapeutics AG (CRSP) Surges 12.4%: Is This an Indication of Further Gains?

CRISPR Therapeutics AG and Vertex Pharmaceuticals are one step closer to gaining approval for their CRISPR/Cas9 gene editing therapy for Sickle Cell Disease and beta thalassemia. An FDA Advisory Committee raised a few concerns about the safety of the therapy yesterday, indicating a positive outlook for approval. The therapy has shown compelling efficacy in clinical trials, offering a potential cure for a debilitating disease that affects >100k.

CRISPR Therapeutics: Positive Exa-Cel AdCom Opens Door For Historic Approval

The FDA appears likely to approve Crispr's gene-editing approach to sickle cell disease, analysts said Wednesday as CRSP stock gapped higher.

Crispr Therapeutics Rallies On Bullish Views Of First-Ever Gene-Editing Drug

After being halted yesterday during the deliberations of a Food and Drug Administration (FDA) advisory committee, CRISPR Therapeutics (NASDAQ: CRSP ) stock is rallying 5% today in early trading. That's because the FDA panel appeared to view the company's treatment for sickle cell anemia, exa-cel, as safe.

CRSP Stock Alert: Can CRISPR Therapeutics Short Squeeze Higher?

Crispr Therapeutics AG's stock CRSP rallied 17% in premarket trade Wednesday, after a positive meeting of a . Food and Drug Administration advisory panel on the gene-editing drug exa-cel developed by Crispr and partner Vertex Pharmaceuticals VRTX as a treatment for sickle-cell disease.

Crispr Therapeutics' stock soars premarket after positive meeting of FDA panel on sickle-cell disease therapy

A panel of advisers to the U.S. health regulator said on Tuesday Vertex Pharmaceuticals and CRISPR Therapeutics could assess potential safety risks of their sickle cell disease gene therapy after approval.

FDA panel says Vertex/CRISPR to assess safety risks of gene therapy in follow-up study

-Exa-cel PDUFA target action date is December 8, 2023 for severe sickle cell disease (SCD)- ZUG, Switzerland and BOSTON, Oct. 31, 2023 (GLOBE NEWSWIRE) -- CRISPR Therapeutics (Nasdaq: CRSP) today announced the completion of the U.S. Food and Drug Administration's (FDA) Cellular, Tissue, and Gene Therapies Advisory Committee meeting for exagamglogene autotemcel (exa-cel) for the treatment of SCD in people ages 12 and older with recurrent vaso-occlusive crises (VOCs). Exa-cel is the first potential therapy to emerge from a strategic partnership between CRISPR Therapeutics and Vertex Pharmaceuticals.

CRISPR Therapeutics Announces Completion of FDA Advisory Committee Meeting for Exagamglogene Autotemcel (exa-cel) for Severe Sickle Cell Disease

The decision by an advisory committee may lead to Food and Drug Administration approval of the first treatment for humans that uses the CRISPR gene-editing system.

Panel Tells F.D.A. That CRISPR Sickle Cell Cure Is Safe Enough for Patients

Nearly all patients treated so far have been relieved of the blood-clogging crises of the disease.

FDA Advisors Consider Crispr Gene-Editing Treatment for Sickle Cell Anemia

Among the more prominent gene-editing stocks on the market, investors in this space pay particularly close attention to CRISPR Therapeutics (NASDAQ: CRSP ). That's due to the fact that CRISPR is among the leading players in the high-growth biotech industry developing gene-based medicines using CRISPR/Cas9 gene-editing technology.

CRSP Stock Halt: CRISPR Trading Halted Ahead of FDA Decision

CRISPR Therapeutics AG (CRSP) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

News for CRISPR Therapeutics Stock (CRSP)